According to ADA guidelines, which diabetes medication class is associated with the most weight loss?

According to ADA guidelines, which diabetes medication class is associated with the most weight loss?

• A. Insulin
• B. SGLT2 inhibitors
• C. GLP-1 receptor agonists
• D. DPP-4 inhibitors

Answer: (C)

In diabetes care, the impact of a medication on body weight is a key consideration, because weight changes can influence overall cardiovascular risk and glycemic control. Among the options, the class that yields the most weight loss is GLP-1 receptor agonists. These drugs act in several ways that reduce weight: they suppress appetite, promote a feeling of fullness, and slow gastric emptying, which together lead to a lower caloric intake. Clinically, these effects translate into meaningful weight loss over time, typically greater than what is seen with other diabetes medications. SGLT2 inhibitors also promote weight loss, but usually to a smaller extent, mainly through the loss of calories in the urine as glucose is excreted. Insulin, on the other hand, can cause weight gain due to its anabolic effects and potential for increased calories stored after hypoglycemia episodes. DPP-4 inhibitors are generally weight neutral. So, the option associated with the greatest weight reduction is the GLP-1 receptor agonist class.

In diabetes care, the impact of a medication on body weight is a key consideration, because weight changes can influence overall cardiovascular risk and glycemic control. Among the options, the class that yields the most weight loss is GLP-1 receptor agonists. These drugs act in several ways that reduce weight: they suppress appetite, promote a feeling of fullness, and slow gastric emptying, which together lead to a lower caloric intake. Clinically, these effects translate into meaningful weight loss over time, typically greater than what is seen with other diabetes medications.

SGLT2 inhibitors also promote weight loss, but usually to a smaller extent, mainly through the loss of calories in the urine as glucose is excreted. Insulin, on the other hand, can cause weight gain due to its anabolic effects and potential for increased calories stored after hypoglycemia episodes. DPP-4 inhibitors are generally weight neutral. So, the option associated with the greatest weight reduction is the GLP-1 receptor agonist class.